Monday, May 15, 2023
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Progress Continues In Influenza and COVID-19 Programs. Cocrystal has been using its proprietary structure-based drug discovery and protein engineering technology to develop novel antiviral drugs. Its lead programs in influenza and COVID-19 (the SARS-CoV-2 virus) have reported progress and have new clinical trials ahead in 2023. Other programs are continuing through preclinical development.
Influenza Phase 2a Expected Shortly. Cocrystal has presented preliminary data from its Phase 1 trial for CC-42344 in influenza in December 2022. A Phase 2a trial testing the drug in a human challenge study is expected to begin in 2Q23. This study uses controlled conditions to test efficacy in healthy human volunteers, allowing for a smaller trial with less variance.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.